2026 Physicians Safety 
Pharma Marketing Network
MAY 12, 2021
Billion by 2026 with a CAGR of 37.2% Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. Wearable technology allows physicians to check in on the health of their patients in between physical office visits. over the Forecast Period.”.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 10, 2023
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
Clarivate
AUGUST 27, 2024
Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Abbott’s Volt should join the party in early 2026. Adagio Medical Inc.,
Nixon Gwilt Law
JANUARY 14, 2025
Venture investment skyrocketed, partnerships between leading AI startups and health systems took shape, and policymakers across the globe grappled with AIs implications for consumer safety and algorithmic transparency. Towards the end of 2024, California passed numerous bills relating specifically to generative AI.
Expert insights. Personalized for you.
59 
Let's personalize your content